<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681599</url>
  </required_header>
  <id_info>
    <org_study_id>AGP aerosol 002</org_study_id>
    <nct_id>NCT04681599</nct_id>
  </id_info>
  <brief_title>Different Modalities in Reducing Airborne Particulate Concentrations During AGP for Health Volunteers</brief_title>
  <official_title>Comparison of Different Modalities in Reducing Airborne Particulate Concentrations During Aerosol Generating Procedures for Health Volunteers: a Randomized Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several clinical procedures have been described as aerosol generating procedure (AGP),&#xD;
      including nebulization, high-flow nasal cannula oxygen therapy, noninvasive ventilation, and&#xD;
      bronchial hygiene treatment, etc. However, the understanding on the transmission risk of&#xD;
      these treatments is still unclear, particularly the methods to reduce the airborne&#xD;
      particulate concentrations during these treatments are still lacking. This study is aimed to&#xD;
      compare different modalities in reducing airborne particulate concentrations during these&#xD;
      aerosol generating procedures, in order to find the most effective method to reduce particle&#xD;
      concentrations, ultimately to decrease the transmission risk and protect health care&#xD;
      providers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2021</start_date>
  <completion_date type="Actual">April 13, 2021</completion_date>
  <primary_completion_date type="Actual">April 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>aerosol particle concentrations at 1 foot away from subject's face</measure>
    <time_frame>5 mins</time_frame>
    <description>aerosol particle concentrations will be recorded continuously for 5 mins during the use of each device at 1 foot away from subject's face</description>
  </primary_outcome>
  <primary_outcome>
    <measure>aerosol particle concentrations at 3 feet away from subject's face</measure>
    <time_frame>5 mins</time_frame>
    <description>aerosol particle concentrations will be recorded continuously for 5 mins during the use of each device at 3 feet away from subject's face</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>subject's comfort</measure>
    <time_frame>5 minutes after using the device</time_frame>
    <description>subject's comfort will be self-evaluated using a visual numerical scale (VNS) ranging between 1 (very uncomfortable) and 5 (very comfortable)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Transmission, Patient-Professional</condition>
  <arm_group>
    <arm_group_label>Nebulization without filter or scavenger</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject will use a standard nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulization with a filter or scavenger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will use a nebulizer with a filter placed at the other end of nebulizer mouthpice or a scavenger outside the nebulizer mask</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flow nasal cannula</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject will use high-flow nasal cannula at 40 L/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flow nasal cannula with a scavenger face tent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will use high-flow nasal cannula at 40 L/min, with a scavenger face tent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flow nasal cannula with a surgical mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will use high-flow nasal cannula at 40 L/min, with a surgical mask over nasal cannula</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Filter</intervention_name>
    <description>Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases</description>
    <arm_group_label>High-flow nasal cannula with a surgical mask</arm_group_label>
    <arm_group_label>Nebulization with a filter or scavenger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scavenger face tent</intervention_name>
    <description>A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria</description>
    <arm_group_label>High-flow nasal cannula with a scavenger face tent</arm_group_label>
    <arm_group_label>Nebulization with a filter or scavenger</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Ages 18-65, Male or Female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic lung disease, including asthma, COPD, etc.&#xD;
&#xD;
          -  Upper airway anatomical abnormities&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Uncontrolled Diabetes, hypertension, or untreated thyroid disease&#xD;
&#xD;
          -  Has any of the following symptoms in the last 21 days: sore throat, cough, chills,&#xD;
             body aches for unknown reasons, shortness of breath for unknown reasons, loss of&#xD;
             smell, loss of taste, fever at or greater than 100 degrees Fahrenheit.&#xD;
&#xD;
          -  COVID-19 test positive within 21 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. Am J Respir Crit Care Med. 2020 Sep 1;202(5):651-659. doi: 10.1164/rccm.202004-1263PP. Review.</citation>
    <PMID>32543913</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5). pii: 2000892. doi: 10.1183/13993003.00892-2020. Print 2020 May.</citation>
    <PMID>32299867</PMID>
  </results_reference>
  <results_reference>
    <citation>Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C, Martin AR, Rothen-Rutishauser B, Kuehl PJ, Häussermann S, MacLoughlin R, Smaldone GC, Muellinger B, Corcoran TE, Dhand R. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv. 2020 Dec;33(6):300-304. doi: 10.1089/jamp.2020.1615. Epub 2020 Aug 12. Review.</citation>
    <PMID>32783675</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaur R, Weiss TT, Perez A, Fink JB, Chen R, Luo F, Liang Z, Mirza S, Li J. Practical strategies to reduce nosocomial transmission to healthcare professionals providing respiratory care to patients with COVID-19. Crit Care. 2020 Sep 23;24(1):571. doi: 10.1186/s13054-020-03231-8. Review.</citation>
    <PMID>32967700</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aerosol generating procedure</keyword>
  <keyword>high-flow nasal cannula</keyword>
  <keyword>nebulization</keyword>
  <keyword>aerosol therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual participant data would not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

